These innovative molecules represent a significant advancement in the management of type 2 diabetes. Retatrutide, a triple GLP-1 and GIP receptor agonist, demonstrates exceptional efficacy in lowering blood glucose https://tasneembwta381324.frewwebs.com/39128623/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide